AIM IMMUNOTECH INC. Amortization of Debt Issuance Costs
AIM IMMUNOTECH INC. (AIM) reported Amortization of Debt Issuance Costs of $552.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-03-27
- AIM IMMUNOTECH INC. amortization of debt issuance costs for the quarter ending 2024-12-31 was $69.00K.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for the quarter ending 2024-09-30 was -$38.00K.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for the quarter ending 2024-06-30 was $226.00K.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for the quarter ending 2024-03-31 was $44.00K.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for fiscal 2025 was $552.00K, a 83.39% increase from fiscal 2024.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for fiscal 2024 was $301.00K.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for fiscal 2021 was $47.00K, a 58.04% decline from fiscal 2020.
- AIM IMMUNOTECH INC. amortization of debt issuance costs for fiscal 2020 was $112.00K, a 61.11% decline from fiscal 2019.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $552.00K 10-K · filed 2026-03-27 | |||
| 2024-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $31.00K derived: sum of 2 quarters · filed 2026-03-27 | $257.00K derived: sum of 3 quarters · filed 2026-03-27 | $301.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $188.00K derived: sum of 2 quarters · filed 2024-11-14 | $232.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $270.00K 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $44.00K 10-Q · filed 2024-05-15 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $11.00K derived: sum of 3 quarters · filed 2023-03-31 | $47.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.00K derived: sum of 2 quarters · filed 2022-11-14 | $47.00K 10-Q · filed 2022-11-14 | $82.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $47.00K 10-Q · filed 2022-08-15 | $82.00K derived: sum of 3 quarters · filed 2022-08-15 | $117.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $36.00K 10-Q · filed 2022-05-13 | $71.00K derived: sum of 2 quarters · filed 2022-05-13 | $106.00K derived: sum of 3 quarters · filed 2022-05-13 | -$33.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $70.00K derived: sum of 2 quarters · filed 2022-03-31 | -$69.00K derived: sum of 3 quarters · filed 2022-03-31 | $112.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$104.00K derived: sum of 2 quarters · filed 2021-11-15 | $77.00K 10-Q · filed 2021-11-15 | $62.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $42.00K 10-Q · filed 2021-08-16 | $27.00K derived: sum of 3 quarters · filed 2021-08-16 | $259.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $181.00K 10-Q · filed 2021-05-17 | $166.00K derived: sum of 2 quarters · filed 2021-05-17 | $398.00K derived: sum of 3 quarters · filed 2021-05-17 | $434.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $217.00K derived: sum of 2 quarters · filed 2021-03-31 | $253.00K derived: sum of 3 quarters · filed 2021-03-31 | $288.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $232.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $268.00K derived: sum of 2 quarters · filed 2020-11-12 | $303.00K 10-Q · filed 2020-11-12 | $358.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $71.00K 10-Q · filed 2020-08-14 | $126.00K derived: sum of 3 quarters · filed 2020-08-14 | $166.00K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $35.00K 10-Q · filed 2020-05-14 | $90.00K derived: sum of 2 quarters · filed 2020-05-14 | $130.00K derived: sum of 3 quarters · filed 2020-05-14 | $158.00K derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $95.00K derived: sum of 2 quarters · filed 2020-03-30 | $123.00K derived: sum of 3 quarters · filed 2020-03-30 | $263.00K 10-K · filed 2020-03-30 |
| 2018-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $68.00K derived: sum of 2 quarters · filed 2019-11-14 | $208.00K 10-Q · filed 2019-11-14 | $232.00K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $168.00K 10-Q · filed 2019-08-14 | $192.00K derived: sum of 3 quarters · filed 2019-08-14 | |
| 2018-03-31 | $140.00K 10-Q · filed 2019-05-15 | $164.00K derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $37.00K 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $13.00K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |